📰 Lantern Pharma News

Page 9 - Lantern Pharma News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Lantern Pharma. Real-time updates on events, politics, business and more.

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting

December 14, 2021

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

Lantern Pharma

Source: prnewswire.com

Allarity Therapeutics Announces Shareholder Acceptance of

December 11, 2021

Press release   Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in...

United States Thomas Pedersen Mike Beyer Chuck Padala Jens Knudsen Company Board Of Directors

Source: globenewswire.com

Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization

November 25, 2021

24.11.2021 - Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S (Allarity A/S or the Company) hereby announces a voluntary offer and offer document to the shareholders of Allarity A/S to acquire all shares in Allarity A/S (the ...

United States Steve Carchedi Thomas Pedersen Mike Beyer Important Information About The Recapitalization Share Exchange Carrotize Pr Communications

Source: wallstreet-online.de

U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.'s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq

November 5, 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United States Thomas Pedersen Mike Beyer Us Securities Exchange Commission Important Information About The Recapitalization Share Exchange Recapitalization Share Exchange

Source: apnews.com

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

November 4, 2021

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

United States David Waldman Jianli Zhou Nicholas Koulermos American Society Of Hematology Exchange Commission On

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

November 4, 2021

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

United States David Waldman Jianli Zhou Nicholas Koulermos American Society Of Hematology Exchange Commission On

Source: prnewswire.com

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights

November 1, 2021

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

United States David Waldman Igor Astsaturov Nicholas Koulermos Kishorg Bhatia Johns Hopkins University

Source: prnewswire.com

Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug Development

October 27, 2021

/PRNewswire/ -- Code Ocean, the leading computational research environment for sharing scientific discoveries, today announced a collaboration that will power...

United States Nicholas Koulermos David Butler Simon Adar Peter Carr Georgetown University

Source: prnewswire.com

Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations

October 27, 2021

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

United States Johns Hopkins Simon Adar Georgetown University National Cancer Institute Exchange Commission On

Source: prnewswire.com